News
Novo Nordisk, FDA and Wegovy
Digest more
GlobalData on MSN1d
Madrigal wins European MASH approval as Novo rivalry looms
Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...
The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...
The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.
Novo Nordisks stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, ...
Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback